343 related articles for article (PubMed ID: 19267392)
1. Analysis of bladder diary with urinary perception to assess overactive bladder symptoms in community-dwelling women.
Honjo H; Kawauchi A; Ukimura O; Nakao M; Kitakoji H; Miki T
Neurourol Urodyn; 2009; 28(8):982-5. PubMed ID: 19267392
[TBL] [Abstract][Full Text] [Related]
2. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
3. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
4. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
5. Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome.
Chung SD; Liao CH; Chen YC; Kuo HC
Neurourol Urodyn; 2011 Sep; 30(7):1300-4. PubMed ID: 21560153
[TBL] [Abstract][Full Text] [Related]
6. Understanding the elements of overactive bladder: questions raised by the EPIC study.
Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
[TBL] [Abstract][Full Text] [Related]
7. Overactive bladder is not only overactive but also hypersensitive.
Lee SR; Kim HJ; Kim A; Kim JH
Urology; 2010 May; 75(5):1053-9. PubMed ID: 20092879
[TBL] [Abstract][Full Text] [Related]
8. Impact of convenience void in a bladder diary with urinary perception grade to assess overactive bladder symptoms: a community-based study.
Honjo H; Kawauchi A; Nakao M; Ukimura O; Kitakoji H; Miki T
Neurourol Urodyn; 2010 Sep; 29(7):1286-9. PubMed ID: 20878998
[TBL] [Abstract][Full Text] [Related]
9. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
11. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.
Kuo HC; Liu HT; Chancellor MB
Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641
[TBL] [Abstract][Full Text] [Related]
12. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
Malone-Lee JG; Al-Buheissi S
BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
[TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
[TBL] [Abstract][Full Text] [Related]
14. Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis.
Hung MJ; Ho ES; Shen PS; Sun MJ; Lin AT; Chen GD;
J Urol; 2006 Aug; 176(2):636-40. PubMed ID: 16813910
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
Steers WD; Herschorn S; Kreder KJ; Moore K; Strohbehn K; Yalcin I; Bump RC;
BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
[TBL] [Abstract][Full Text] [Related]
16. Comparison of sensation-related voiding patterns between continent and incontinent women: a study with a 3-day sensation-related bladder diary (SR-BD).
Naoemova I; De Wachter S; Wyndaele JJ
Neurourol Urodyn; 2008; 27(6):511-4. PubMed ID: 18092332
[TBL] [Abstract][Full Text] [Related]
17. How do urinary diaries of women with an overactive bladder differ from those of asymptomatic controls?
Fitzgerald MP; Ayuste D; Brubaker L
BJU Int; 2005 Aug; 96(3):365-7. PubMed ID: 16042731
[TBL] [Abstract][Full Text] [Related]
18. Aging and overactive bladder may be associated with loss of urethral sensation in women.
Kenton K; Lowenstein L; Simmons J; Brubaker L
Neurourol Urodyn; 2007; 26(7):981-4. PubMed ID: 17626276
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women.
Wennberg AL; Molander U; Fall M; Edlund C; Peeker R; Milsom I
Eur Urol; 2009 Apr; 55(4):783-91. PubMed ID: 19157689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
